Nektar Therapeutics (NASDAQ:NKTR) Receives Average

1 day ago · B. Riley initiated coverage on Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 target price on the stock. HC …

$4.00
OFF

Nektar Therapeutics (NASDAQ:NKTR) Receives Average

2 weeks from now

1 day ago · B. Riley initiated coverage on Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 target price on the stock. HC …

marketbeat.com

$4
OFF

Nektar Initiated With A Buy At B. Riley - Markets Insider

2 weeks from now

Jan 8, 2025 · B. Riley last night initiated coverage of Nektar with a Buy rating and $4 price target The firm views Nektar’s most advanced T regulatory cell targeting candidate, Rezpeg, as on …

businessinsider.com

$4.00
OFF

Nektar Therapeutics (NKTR) Gets A Buy From Piper Sandler

2 weeks from now

6 days ago · In a report released on January 7, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $4.00 price target. See Insiders’ Hot Stocks on TipRanks >>

businessinsider.com

$4.00
OFF

Nektar Therapeutics (NKTR) Gets A Buy From B.Riley Financial

2 weeks from now

Jan 8, 2025 · Nektar Therapeutics (NKTR – Research Report) received a Buy rating and a $4.00 price target from B.Riley Financial analyst Mayank Mamtani yesterday. The company’s shares …

businessinsider.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.With the stock currently trading …

investing.com

$1.14
OFF

B. Riley Begins Coverage On Nektar Therapeutics (NASDAQ:NKTR)

2 weeks from now

6 days ago · NASDAQ NKTR opened at $1.14 on Wednesday. The firm’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.21. Nektar Therapeutics has a …

etfdailynews.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.With the stock currently trading …

investing.com

$4.00
OFF

Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating

2 weeks from now

3 days ago · B. Riley began coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $4.00 target price on the stock. …

marketbeat.com

$4
OFF

Nektar Initiated With A Buy At B. Riley - Nasdaq

2 weeks from now

Jan 8, 2025 · B. Riley initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target Stay Ahead of the Market:Discover outperforming stocks and invest smarter with Top Smart …

nasdaq.com

$4
OFF

Nektar Initiated With A Buy At B. Riley | Markets Insider

2 weeks from now

Jan 8, 2025 · B. Riley initiated coverage of Nektar (NKTR) with a Buy rating and $4 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, …

businessinsider.com

$4
OFF

Analysts Initiate Coverage On Top Stocks: Levi Strauss, Summit ...

2 weeks from now

6 days ago · Nektar Therapeutics has been initiated with a Buy rating and a $4 price target by B. Riley Securities analyst Mayank Mamtani. ... Truist Securities analyst Asthika Goonewardene …

ainvest.com

15%
OFF

Mayank Mamtani - Analyst At B. Riley Securities - Stock Analysis

2 weeks from now

Jan 8, 2025 · Mayank Mamtani is a Wall Street analyst working for B. Riley Securities. Mayank has covered 32 stocks with a 46.15% success rate and an average return of 38.01%. ...

stockanalysis.com

$7.00
OFF

What Is B. Riley’s Forecast For NKTR FY2024 Earnings?

2 weeks from now

4 days ago · Finally, Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 …

etfdailynews.com

$4
OFF

B. Riley Securities Initiates Coverage On Nektar Therapeutics

2 weeks from now

Jan 8, 2025 · B.Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

moomoo.com

$4.00
OFF

Nektar Stock Positioned For Growth As B. Riley Forecasts REZPEG As …

2 weeks from now

Jan 8, 2025 · On Wednesday, B.Riley initiated coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) with a Buy rating and a price target of $4.00.With the stock currently trading …

investing.com

$4
OFF

B. Riley Securities Initiates Coverage On Nektar Therapeutics With …

2 weeks from now

Jan 8, 2025 · B. Riley Securities analyst Mayank Mamtani initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $4.

sahmcapital.com

FAQs about Nektar Therapeutics (NASDAQ:NKTR) Receives Average Coupon?

Should you buy Nektar Therapeutics (NKTR)?

Fintel reports that on January 8, 2025, B. Riley Securities initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a Buy recommendation. Analyst Price Forecast Suggests 302.86% Upside As of December 23, 2024, the average one-year price target for Nektar Therapeutics is $4.79/share. The forecasts range from a low of $1.31 to a high of $7.35. ...

What is the average price target for Nektar Therapeutics (Nektar)?

As of December 23, 2024, the average one-year price target for Nektar Therapeutics is $4.79/share. The forecasts range from a low of $1.31 to a high of $7.35. The average price target represents an increase of 302.86% from its latest reported closing price of $1.19 / share. See our leaderboard of companies with the largest price target upside. ...

How many funds own Nektar Therapeutics (NKTR)?

There are 264 funds or institutions reporting positions in Nektar Therapeutics. This is an increase of 50 owner (s) or 23.36% in the last quarter. Average portfolio weight of all funds dedicated to NKTR is 0.04%, an increase of 7.78%. Total shares owned by institutions increased in the last three months by 9.26% to 168,130K shares. ...

How did Nektar Therapeutics perform compared to last year?

Based on Nektar Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $24.12 million and a GAAP net loss of $37.06 million. In comparison, last year the company earned a revenue of $24.14 million and had a GAAP net loss of $45.84 million ...

Who is Nektar Therapeutics?

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. ...

Does Eventide asset management own NKTR?

Eventide Asset Management holds 9,400K shares representing 5.10% ownership of the company. In its prior filing, the firm reported owning 7,529K shares , representing an increase of 19.90%. The firm increased its portfolio allocation in NKTR by 31.79% over the last quarter. ...